6.
Moderna Inc. Moderna COVID-19 Variant Vaccines [slides presented at Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting June 15, 2023] [Internet]. Food and Drug Administration (FDA); 2023 Jun 15 [cited 2023 Jul 17]. Available from:
https://www.fda.gov/media/169539/download.
8. National Advisory Committee on Immunization (NACI). NACI rapid response: Booster dose in long-term care residents and seniors living in other congregate settings 2021.
10. Canadian Blood Services. COVID-19 Seroprevlance Report: Report #22. 2022.
14. Moore SC, Kronsteiner B, Longet S, Adele S, Deeks AS et al. Evolution of long-term hybrid immunity in healthcare workers after different COVID-19 vaccination regimens: a longitudinal observational cohort study. medRxiv. 2022:1-49.
15. Stamatatos L, Czarostki J, Wan Y-H, Homad LJ, Rubin V et al. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science. 2021;372(6549):1413-8.
18. Bobrovitz N, Ware H, Ma X, Li Z, Hosseini R, Cao C, et al. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. The Lancet Infectious Diseases. 2023.
20. Chen H, Huang Z, Chang S, Hu M, Lu Q, Zhang Y, Wang H, Xiao Y, Ge Y, Zou Y, Cui F. Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (Sinopharm BBIBP-CorV) coadministered with quadrivalent split-virion inactivated influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in China: A multicentre, non-inferiority, open-label, randomised, controlled, phase 4 trial. Vaccine. 2022;40(36):5322-32.
21. Izikson R, Brune D, Bolduc JS, Bourron P, Fournier M, Moore TM, Pandey A, Perez L, Sater N, Shrestha A, Wague S. Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged≥ 65 years: a phase 2, randomised, open-label study. The Lancet Respiratory Medicine. 2022;10(4):392-402.
22. Lazarus R, Baos S, Cappel-Porter H, Carson-Stevens A, Clout M, Culliford L, Emmett SR, Garstang J, Gbadamoshi L, Hallis B, Harris RA. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial. The Lancet. 2021;398(10318):2277-87.
23. Toback S, Galiza E, Cosgrove C, Galloway J, Goodman AL, Swift PA, Rajaram S, Graves-Jones A, Edelman J, Burns F, Minassian AM. Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine 2022;10(2):167-79.
24. Janssen C, Mosnier A, Gavazzi G, Combadière B, Crepey P, Gaillat J, Launay O, Botelho-Nevers E. Coadministration of seasonal influenza and COVID-19 vaccines: A systematic review of clinical studies. . Human Vaccines & Immunotherapeutics. 2022;2131166.
25. Shenyu W, Xiaoqian D, Bo C, Xuan D, Zeng W, Hangjie Z, Qianhui Z, Zhenzhen L, Chuanfu Y, Juan Y, Gang Z. Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine (CoronaVac) co-administered with an inactivated quadrivalent influenza vaccine: A randomized, open-label, controlled study in healthy adults aged 18 to 59 years in China. Vaccine. 2022;40(36):5356-65.
26. Domnich A, Orsi A, Trombetta CS, Guarona G, Panatto D, Icardi G. COVID-19 and Seasonal Influenza Vaccination: Cross-Protection, Co-Administration, Combination Vaccines, and Hesitancy. Pharmaceuticals. 2022;15(3):322.
27. Bentov Y, Beharier O, Moav-Zafrir A, et al. Ovarian follicular function is not altered by sars-cov-2 infection or bnt162b2 mrna covid-19 vaccination. Hum Reprod. 2021;36(18):2506-13.
28. Wang M, Yang Q, Ren X, et al. Investigating the impact of asymptomatic or mild sarscov-2 infection on female fertility and in vitro fertilization outcomes: A retrospective cohort study. EClinicalMedicine. 2021;38:101013.
31. Villar J, Conti CP, Gunier RB, Ariff S, Craik R, Cavoretto PI, Rauch S, Gandino S, Nieto R, Winsey A, Menis C, et al. Pregnancy outcomes and vaccine effectiveness during the period of omicron as the variant of concern, INTERCOVID-2022: a multinational, observational study. Lancet. Feb 2023;401:447-57.
32. Allotey J, Fernandez S, Bonet M, Stallings E, Yap M, Kew T, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. bmj. 2020;370.
33. Prabhu M, Riley L. Coronavirus disease 2019 (COVID-19) vaccination in pregnancy. Obstetrics & Gynecology. Mar 2023;141(3):473-82.
34. Shimabukuro TT, Kim SY, Myers TR, Moro PL, Oduyebo T, Panagiotakopoulos L, Marquez PL, Olson CK, Liu R, Chang KT, Ellington SR, Burkel VK, Smoots AN, Green CJ, Licata C, Zhang BC, Alimchandani M, Mba-Jonas A, Martin SW, Gee JM, Meaney-Delman DM. CDC v-safe COVID-19 Pregnancy Registry Team. Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons. N Engl J Med. 2021;384:2273-82.
35. Castillo E and Poliquin V. Immunization in pregnancy. J Obstet Gynaecol Can [Internet]. 2018;40(4):478-89.
39. Saleh E, Moody MA, Walter EB. Effect of antipyretic analgesics on immune responses to vaccination. Hum Vaccin Immunother [Internet]. 2016.;12(9):2391-402.
40. Chau-Giendinning H, Baber B, Neher JO, Safranek S. Do prophylactic antipyretics reduce vaccination-associcated symptoms in children? J Fam Pract [Internet]. 2021;69(3):E21-2.
41. Das RR, Panigrahi I, Naik SS. The effect of prophylactic antipyretic administration on post-vaccination adverse reactions and antibody response in children: a systematic review. PLoS One [Internet]. 2021;69(3):e106629.
42. Li C., Chen Y., Zhao, Y., et al. Intravenous injection of COVID-19 mRNA vaccine can induce acute myopericarditis in mouse model. Clin Infect Dis. 2021;ciab707.
43. Nicolai L, Leunig A, Pekayvaz K, et al. Thrombocytopenia and splenic platelet directed immune responses after intravenous ChAdOx1 nCov-19 administration. bioRxiv [Preprint]. 2021.
44. Public Health Agency of Canada. Canadian Immunization Guide [Internet]. Evergreen ed. Part 1 - Key Immunization Information: Vaccine Administration Practices. 2017. Available from:
47. Moshe Ipp, Anna Taddio, Jonathan Sam, Morton Goldbach, and Patricia C Parkin. Vaccine‐related pain: randomised controlled trial of two injection techniques. 2007.